The Human Microbiome: Biomedical Implications and Birth of a Market

NEEDHAM, MASSACHUSETTS, UNITED STATES, November 18, 2014 /EINPresswire.com/ -- Cambridge Healthtech Institute’s Insight Pharma Reports announces the The Human Microbiome: Biomedical Implications and Birth of a Market report, authored by Kenneth Rubenstein, Ph.D.

This new report covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet,diagnostics, contributions in health and disease, and infectious disease.

Report Features Include:

• In-depth analysis of market data
• Exclusive interview transcripts with the following experts:
o Peter DiLaura, President & CEO, Second Genome
o Colleen Cutcliffe, CEO, Whole Biome
o James Brown, PhD; Head, Computational Biology; Head, Microbiome Matrix Team; GlaxoSmithKline
o Jack Gilbert, PhD., Environmental Microbiologist, Assoc. Prof., Department of Ecology & Evolution, Argonne National Laboratory
o Glenn Tillotson, PhD, Senior Partner, Transcrip Partners, USA
o Peter P. Lee, MD, Executive Chairman, Osel, Inc.
o Gregory Kuehn, VP Business Development and Marketing, Metabiomics
o Stephen Elms, CEO, Miomics Bio-Therapeutics
o Sydney M. Finegold, M.D., Emeritus Professor of Medicine, and Emeritus Professor of Microbiology, Immunology, and Molecular Biology, UCLA School of Medicine; Staff Physician, Infectious Disease Section, VA Greater Los Angeles Healthcare System

Companies covered in this report include:

• 4D Pharma
• ActoGenixAOBiome
• AvidBiotics
• CIPAC Limited
• Enterome Bioscience
• Human Longevity
• Metabiomics
• Microbiome Therapeutics
• Miomics
• OmniBiome Therapeutics
• OptiBiotix
• Osel Inc
• OxThera
• PathoGenetix
• Rebiotix
• Ritter Pharmaceuticals
• Second Genome
• Seres Health
• uBiome
• UCB
• UC San Francisco
• Vedanta ViThera Pharmaceuticals
• Whole Biome


For more information and to purchase this Insight Pharma Report, visit: www.InsightPharmaReports.com

About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. www.InsightPharmaReports.com

Kerri Simpson
Cambridge Healthtech Institute
7819721347
email us here